Psyence Biomedical Ltd.’s Price-to-Book Ratio at a glance
Psyence Biomedical Ltd. reports price-to-book ratio of 0x for Mar 2025. The prior period recorded -355.5x (Mar 2024). Year over year the metric moved +355.48 (+100%). The rolling three-period average stands at 105.8x. Data last refreshed Nov 20, 2025, 7:09 PM.
Latest reading
0x · Mar 2025
YoY movement
+355.48 (+100%)
Rolling average
105.8x
Current Price-to-Book Ratio
0x
+355.48
+100%
Rolling average
105.8x
Latest Value
0x
Mar 2025
YoY Change
+355.48
Absolute
YoY Change %
+100%
Rate of change
3-Period Avg
105.8x
Smoothed
Narrative signal
Psyence Biomedical Ltd.’s price-to-book ratio stands at 0x for Mar 2025. Year-over-year, the metric shifted by +355.48, translating into a +100% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-book ratio shapes Psyence Biomedical Ltd.'s story
As of Mar 2025, Psyence Biomedical Ltd. reports price-to-book ratio of 0x. Monitor price-to-book trends to gauge how investors value tangible assets and equity on the balance sheet.
Capital-intensive industries
Banks, insurers, and industrials rely on P/B to judge returns on equity relative to book value.
Reading discount or premium
Ratios below 1.0 signal the market values equity below book, which could mean undervaluation or weak profitability.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Psyence Biomedical Ltd. (PBM) FAQs
Answers tailored to Psyence Biomedical Ltd.’s price-to-book ratio profile using the latest Financial Modeling Prep data.
What is Psyence Biomedical Ltd.'s current price-to-book ratio?
As of Mar 2025, Psyence Biomedical Ltd. reports price-to-book ratio of 0x. This reading reflects the latest filings and price data for PBM.
How is Psyence Biomedical Ltd.'s price-to-book ratio trending year over year?
Year-over-year, the figure shifts by +355.48 (+100%). Pair this context with revenue growth and free cash flow signals to gauge momentum for PBM.
Why does price-to-book ratio matter for Psyence Biomedical Ltd.?
Price-to-book compares market value with book value of equity, highlighting balance sheet-driven valuation. For Psyence Biomedical Ltd., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Psyence Biomedical Ltd.'s price-to-book ratio above its recent average?
Psyence Biomedical Ltd.'s rolling three-period average sits at 105.8x. Comparing the latest reading of 0x to that baseline highlights whether momentum is building or fading for PBM.
How frequently is Psyence Biomedical Ltd.'s price-to-book ratio refreshed?
Data for PBM was last refreshed on Nov 20, 2025, 7:09 PM and updates automatically every 24 hours, keeping your valuation inputs current.